Neuroendocrine tumors other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 26: | Line 26: | ||
[[Image:Neuroendocrine tumor pancreas 003.jpg|left|thumb|400px|OctreoScan demonstrates abnormal uptake in the head of the pancreas]] | [[Image:Neuroendocrine tumor pancreas 003.jpg|left|thumb|400px|OctreoScan demonstrates abnormal uptake in the head of the pancreas]] | ||
<br clear="left"/> | <br clear="left"/> | ||
==References== | ==References== |
Revision as of 18:31, 10 September 2012
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Neuroendocrine tumors Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Other Imaging Findings
Octreoscan
The diagnostic procedure that utilizes a somatostatin analog is the OctreoScan, also called somatostatin receptor scintigraphy (SRS or SSRS): a patient is injected with octreotide chemically bound to a radioactive substance, often indium-111; for those patients whose tumor cells are avid for octreotide, a radiation-sensitive scan can then indicate the locations of the larger lesions.
An OctreoScan is a relatively crude test that generates subjective results.